Výsledky vyhledávání - "Rhonda, Jensen"

A Virtual Leadership Program's Impact on Employee Leadership Development at a Healthcare Organization

Autor: Charlene, Banta, Kelly, Doran, Erin, Duncan, Patty, Heiderscheit, Rhonda, Jensen, Jenny, Jorgenson, Barb, Rechtzigel, Sarah, Shtylla

Publikováno v: Perspect Health Inf Manag

In this study, we explored the effectiveness of the virtual organizational leadership development program at Mayo Clinic. The purpose of this study was to explain how a virtual leadership development program impacted employee leadership efficacy. The

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a2d00709d817490d821050a5c75480f5
https://pubmed.ncbi.nlm.nih.gov/34035784

Zobrazit plný text záznamu

Nontoxic Suramin as a Chemosensitizer in Patients: Dosing Nomogram Development

Autor: Sae Heum Song, Miguel A. Villalona-Calero, Teng Kuang Yeh, Danny Chen, M. Guillaume Wientjes, Michael R. Grever, Rhonda Jensen, Liang Zhao, Jessie L.-S. Au, Anthony J. Murgo, Gregory A. Otterson

Publikováno v: Pharmaceutical Research. 23:1265-1274

We reported that suramin produced chemosensitization at nontoxic doses. This benefit was lost at the approximately 10-fold higher, maximally tolerated doses (MTD). The aim of the current study was to identify in patients the chemosensitizing suramin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ed581589f9184d922a2bfb15b2dd63e
https://doi.org/10.1007/s11095-006-0165-1

Zobrazit plný text záznamu

A Phase I Study of Interleukin 12 with Trastuzumab in Patients with Human Epidermal Growth Factor Receptor-2-Overexpressing Malignancies

Autor: Rhonda Jensen, Adrian Lewis, Donn C. Young, Julie Dierksheide, Charles L. Shapiro, Padma Nadella, Cynthia M. Magro, Carrie De Hoff, Robin Parihar, Anne M. VanBuskirk, William E. Carson

Publikováno v: Clinical Cancer Research. 10:5027-5037

Purpose: On the basis of preclinical studies, we hypothesized that interleukin (IL)12 would potentiate the antitumor actions of an antihuman epidermal growth factor receptor-2 (HER2) monoclonal antibody (trastuzumab). We conducted a Phase I trial to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2384cc4495176c3e1cf23f0b14531959
https://doi.org/10.1158/1078-0432.ccr-04-0265

Zobrazit plný text záznamu

Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes

Autor: Tong Shen, Maryam B. Lustberg, Amy S. Ruppert, Michael Berger, Michael R. Grever, Yong Wei, Rhonda Jensen, Shubham Pant, Ewa Mrozek, Lisa A. Brenner, Charles L. Shapiro, Ling Chen, Donna R. Shiels, Bhuvaneswari Ramaswamy, M. Guillaume Wientjes, Jessie L.-S. Au

Publikováno v: Cancer chemotherapy and pharmacology. 70(1)

Suramin, a polysulfonated naphthylurea, inhibits the actions of polypeptide growth factors including acidic and basic fibroblast growth factors (aFGF and bFGF), which confer broad spectrum chemotherapy resistance. We hypothesized that suramin at non-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f702e4e75b4e277807c6bb7c53a92c2c
https://pubmed.ncbi.nlm.nih.gov/22729159

Zobrazit plný text záznamu

A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma

Autor: Gregory B. Lesinski, Donn C. Young, Kimberly A. Varker, Jennifer E. Biber, Haifeng Wu, Michael Walker, Helen X. Chen, Kari Kendra, Rhonda Jensen, Amy Lehman, William E. Carson, Cheryl Kefauver

Publikováno v: Annals of surgical oncology. 14(8)

Vascular endothelial growth factor (VEGF) is a proangiogenic molecule produced by melanoma cells. We hypothesized that administration of bevacizumab (Bev), a monoclonal antibody that neutralizes VEGF, with low-dose interferon alfa-2b (IFN-alpha2b), a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8565ecbb168a6319ec4a710b20094d52
https://pubmed.ncbi.nlm.nih.gov/17534686

Zobrazit plný text záznamu

A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients

Autor: Robin, Parihar, Padma, Nadella, Adrian, Lewis, Rhonda, Jensen, Carrie, De Hoff, Julie E, Dierksheide, Anne M, VanBuskirk, Cynthia M, Magro, Donn C, Young, Charles L, Shapiro, William E, Carson

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 10(15)

On the basis of preclinical studies, we hypothesized that interleukin (IL)12 would potentiate the antitumor actions of an antihuman epidermal growth factor receptor-2 (HER2) monoclonal antibody (trastuzumab). We conducted a Phase I trial to determine

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::901bec017d06db3a35e1c78ac6748f3f
https://pubmed.ncbi.nlm.nih.gov/15297404

Zobrazit plný text záznamu

Modulation of chemotherapy resistance with low dose suramin in refractory non-small cell lung cancer (NSCLC) patients: A phase I study of sequential non-cross resistant chemotherapy

Autor: Greg Otterson, M. A. Villalona Calero, Teng-Kuang Yeh, T. Olencki, T. Saab, A. Grainger, Rhonda Jensen, Jessie L.-S. Au, Donn C. Young, G. Wientjes

Publikováno v: Journal of Clinical Oncology. 23:2104-2104

2104 Background: Primary and acquired chemotherapy resistance have been primary determinants of poor outcome in pts with metastatic NSCLC. Over expression of mdr-1 glycoprotein and glutathione and ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2aae89bfc847041c268a1ad29c6edc65
https://doi.org/10.1200/jco.2005.23.16_suppl.2104

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání